Cardiomyocyte proliferation gradually declines during embryogenesis resulting in severely limited regenerative capacities in the adult heart. Understanding the developmental processes controlling cardiomyocyte proliferation may thus identify new therapeutic targets to modulate the cell-cycle activity of cardiomyocytes in the adult heart. This study aims to determine the mechanism by which fibroblast growth factor 10 (FGF10) controls foetal cardiomyocyte proliferation and to test the hypothesis that FGF10 promotes the proliferative capacity of adult cardiomyocytes.
Introduction
Precise spatiotemporal control of proliferation at multiple steps of heart development is crucial for proper cardiogenesis. At early stages of heart development, regulated proliferation of second heart field progenitor cells is required for normal heart tube elongation. 1 During foetal heart development, ventricular chamber growth is achieved by extensive cardiomyocyte proliferation, impairment of which results in congenital heart defects. 2 The rate of cardiomyocyte proliferation decreases rapidly during the first week of postnatal life, as cardiac growth transitions from hyperplastic to hypertrophic. 3 Despite a low but detectable level of adult cardiomyocyte turnover, 4 ,5 complete regeneration after injury does not occur in the adult mammalian heart. In contrast, the postnatal mouse heart possesses extensive regenerative capacities that are lost within the first week of postnatal life, 6 coinciding with the developmental time window during which cardiomyocytes become binucleated and withdraw from the cell-cycle. 7 Insight into the developmental processes controlling cardiomyocyte proliferation may therefore lead to potential new therapeutic targets to modulate the cell-cycle activity of adult cardiomyocytes. 8 Despite recent advances in our understanding of cardiac growth, the molecular mechanisms controlling foetal cardiomyocyte proliferation remain poorly defined. In addition to cell-autonomous mechanisms, paracrine signals originating from the endocardium, epicardium, and cardiac fibroblasts have been implicated. 9 Fibroblast growth factor (FGF) signalling controls multiple developmental processes including proliferation, differentiation, and migration. 10 FGF signalling pathways comprise 22 ligands that act through binding and activation of seven cell surface tyrosine kinase receptors (FGF receptors; FGFRs) with distinct binding properties. 11 FGF signals, in particular FGF8, are known to control the early proliferation of cardiac progenitor cells in the second heart field. 1 In the foetal heart, multiple FGF ligands, including FGF9, FGF16, and FGF20, have been shown to regulate cardiomyocyte proliferation from epicardial and endocardial expression domains. Indeed mutant mice for Fgf9 and Fgf16 display congenital heart defects associated with decreased foetal cardiomyocyte proliferation. 12 -14 Although the gene encoding FGF10 is prominently expressed in second heart field cardiac progenitor cells, 15 and cardiogenic specification of embryonic stem cells has been suggested to require FGF10, 16 loss of Fgf10 has no major impact on early steps of heart development, likely as a result of functional redundancy between FGF10 and FGF8 17 and FGF3 18 during this time period. Fgf10 null embryos, nevertheless, present altered heart morphology at foetal stages with abnormal positioning of the ventricular apex in the thoracic cavity. 19 Furthermore, FGF10 signalling, through the epicardial expression of FGFR1 and FGFR2, has been suggested to regulate epicardial-derived cell migration into the compact myocardial layer, resulting in a deficit in cardiac fibroblast formation and reduced foetal cardiomyocyte proliferation in Fgf10 2/2 hearts. 20 In this study, we demonstrate that FGF10 signalling drives a regional cardiomyocyte proliferative program operative in the right ventricle. Analysis of Fgf10 mutant hearts shows altered right-ventricular cardiomyocyte proliferation associated with decreased right-ventricular wall thickness and abnormal heart morphology. We show that FGF10 signalling leads to the phosphorylation of FOXO3 in right-ventricular cardiomyocytes through a cell-type autonomous mechanism that in turn induces decreased expression of the cyclin-dependent kinase inhibitor p27 kip1 and promotes proliferation. Furthermore, in adult hearts, conditional Fgf10 overexpression results in a rapid induction of cardiomyocyte cell-cycle re-entry leading to increased ventricular wall thickness, identifying FGF10 as a potential target for cardiac repair.
Methods
Detailed experimental methods are provided in the Supplementary material online.
Mice
For details of mouse lines used see Supplementary material online. Mouse care and procedures were approved by the Departmental Direction of Veterinary Services of the French Ministry of Agriculture and the local ethics committee.
Cell isolation and primary culture
Heart cells from E17.5 -E18.5 Fgf10 +/+ and Fgf10 2/2 hearts were enzymatically isolated and cultured as described in the Supplementary material online.
Immunofluorescence
Paraffin sections and primary heart cells from E17.5 -E18.5 Fgf10 +/+ and Fgf10 2/2 hearts and paraffin sections from adult hearts were treated as described in the Supplementary material online.
Morphogenic parameters and cross-sectional area measurements
Parameters were measured on digitally recorded images using the Axiovison software package (Zeiss, Germany) as described in the Supplementary material online.
Proliferation analysis
Foetal proliferation was assessed using bromodeoxyuridine (BrdU) and Ki-67 immunofluorescence (IF) on paraffin sections and primary cultured cells, respectively, as described in the Supplementary material online. Proliferation in adult hearts was examined on paraffin sections using Ki-67 and PH3 IF as described in Supplementary material online.
Real-time qPCR
Total RNA extraction, qRT -PCR analysis, and primer sequences are described in the Supplementary material online.
Immunoblotting
Protein abundance of FGF10, NKX2-5, p21 cip1 , p27 kip1 , phospho-FOXO1, and phospho-FOXO3A was determined using western blot analysis performed as described in the Supplementary material online.
Fluorescence-activated cell sorting
E18.5 heart cell populations were isolated using a FACSAriaIII SORP cell sorter as described in the Supplementary material online, and data analysis was performed using DIVA software (Becton Dickinson).
Statistical analysis
All data are expressed as means + SEM. The number (n) of experiments is shown in figure legends. Statistical significance was determined by Student's t-test and two-way ANOVA approach.
Results

FGF10 is required for normal right-ventricular morphogenesis
Fgf10 mutant embryos die at birth with severe alteration of diverse developmental processes including failure of lung and limb formation. 21, 22 While early heart development appears normal in the absence of FGF10, Marguerie et al., 19 demonstrated that Fgf10 2/2 foetal hearts present altered heart morphology with abnormal positioning of the cardiac apex in the thoracic cavity. Using high-resolution episcopic microscopy (HREM), we confirmed that while Fgf10 deletion did not affect cardiac looping or septation, Fgf10 mutant embryos displayed abnormal ventricular morphology at embryonic day (E) 18.5 ( Figure 1A -D and movies 1 and 2), including abnormal positioning of the cardiac apex and a thin right-ventricular myocardial wall. Quantitative measurement of the thickness of the compact ventricular wall using histological sections ( Figure 1E -G) and HREM-3D-reconstructed hearts (Supplementary material online, Figure S1A ) showed that while left-ventricular wall thickness is not affected, the right-ventricular wall is markedly hypoplastic in Fgf10 2/2 embryos. As a result, the LV/RV wall thickness ratio increases from 1.18 + 0.1 in wild type to 1.6 + 0.07 in Fgf10
embryos (Supplementary material online, Figure S1B ; P , 0.05). The measurement of cardiomyocyte cross-sectional area did not reveal any alteration of cell size in Fgf10 2/2 hearts ( Figure 1H ; Supplementary material online, Figure S1C ), suggesting that reduced right-ventricular wall thickness may result from a decrease in cardiac cell numbers in the free right-ventricular wall.
FGF10 controls foetal right-ventricular myocyte proliferation
We then investigated whether cell proliferation is affected in Fgf10 mutant hearts. Global heart cell proliferation was first evaluated on Fgf10 mutant and control heart sections by scoring incorporation of BrdU relative to the total number of nuclei. While no alteration in Figure 2A and B). After cardiomyocytes, cardiac fibroblasts are the most numerous cell type in the heart and are known to play essential roles in heart function, including organization of the myocyte contractile network and the regulation of cardiomyocyte proliferation. To determine the role of FGF10 in the regulation of foetal cardiomyocyte vs. fibroblast proliferation, primary cultures of free ventricular wall cells from E18.5 wild type and Fgf10 2/2 hearts were evaluated for proliferation using the proliferation FGF10 controls cardiomyocyte proliferation marker Ki-67 ( Figure 2C ). Cardiomyocytes and fibroblasts were distinguished using a-actinin and vimentin antibodies, respectively. While the percentage of Ki-67-positive left-ventricular cardiomyocytes was similar in Fgf10 +/+ and Fgf10 2/2 cultures, significantly decreased cardiomyocyte proliferation was observed in right-ventricular cultures ( Figure 2D ).
No proliferation defect was observed in fibroblasts ( Figure 2E Figure S2 ).
Together, these results suggest that FGF10 is required for maximal foetal cardiomyocyte proliferation in the right ventricle.
3.3 FGF10 regulates cardiomyocyte proliferation through FOXO3 phosphorylation and down-regulation of p27 kip1 expression
Using a candidate approach, we investigated the downstream mechanism by which FGF10 signalling regulates regional myocyte proliferation in the foetal heart. The modulation of the transcriptional activity of forkhead box O (FOXO) factors is governed by post-translational modifications such as phosphorylation and has been implicated in the regulation of multiple cellular events including proliferation, downstream of growth factor signalling. 23 Indeed, phosphorylated FOXO factors are excluded from the nucleus leading to the inhibition of FOXO-induced transcription including that of the cyclin-dependent kinase inhibitors p21 cip1 and p27 kip1 . 23 FOXO1 and FOXO3 are both expressed in the developing myocardium, and FOXO1 has been recently implicated in the regulation of IGF-induced foetal cardiomyocyte proliferation 24 while FOXO3 has been shown to prevent the development of adult heart hypertrophy. 25 To determine a potential role of FOXO transcription factors in FGF10 regulation of foetal cardiomyocyte proliferation, we investigated the phosphorylation status of FOXO1 and FOXO3 proteins in Fgf10 mutant hearts. Western blot experiments revealed that while FOXO1 phosphorylation was unaltered (Supplementary material online, Figure S3A and B), decreased FOXO3 phosphorylation was observed in the right but not left ventricle of E18.5 Fgf10 2/2 hearts ( Figure 3A and B). In addition, using qRT-PCR, we demonstrated that the decreased FOXO3 phosphorylation levels observed in Fgf10
right ventricles did not result from altered Foxo3 transcript levels ( Figure 3C ). Analysis of expression levels of the cell-cycle inhibitor and FOXO target gene p27 kip1 using western blot and qRT-PCR experiments demonstrated a significant up-regulation in the right but not left 3.4 Receptor and ligand distribution suggests that FGF10 regulates cardiomyocyte proliferation through a cell-type autonomous mechanism
Fgf10 is expressed in early second heart field cardiac progenitor cells and in right-ventricular myocardium at E9.5. 15 Fgf10 mRNA has been detected in the adult mouse heart. 26, 27 We first investigated the expression of Fgf10 in the foetal mouse heart using the Fgf10-enhancer trap transgene Mlc1v-24, an Fgf10 expression reporter line (Supplementary material online, Figure S4 ). 15 Whole mount X-gal stained E15.5
Mlc1v-24 hearts (Supplementary material online, Figure S4A ), b-gal immunodetection on E18.5 Mlc1v-24 cryosections (Supplementary material online, Figure S4B ) and qRT-PCR experiments using mRNA isolated from right and left ventricles of E18.5 Mlc1v-24 hearts (Supplementary material online, Figure S4C ) showed a predominant expression of the transgene in the right compared with the left ventricle. Measurement of endogenous Fgf10 mRNA levels using qRT-PCR ( Figure 4A ) and FGF10 protein levels using western blot experiments ( Figure 4B ) confirmed that, as at E9.5, FGF10 accumulates predominantly in the right ventricle of the foetal heart at E18.5. No FGF10 expression was detected in Fgf10 2/2 hearts, at either the transcript level (data not shown) or the protein level ( Figure 4B ). In contrast, NKX2-5 transcripts and protein accumulate equivalently in the right and left ventricles ( Figure 4C and D) . Cardiac fibroblasts, as already described, are the most numerous cell type in the heart after cardiomyocytes and express specific proteins including the T-cell surface antigen THY1, vimentin, and the discoïdin receptor 2 (DDR2) that are not found in cardiomyocytes. 28 Immunolabelling of cardiomyocytes and fibroblasts using a-actinin and vimentin antibodies, respectively, in E18.5 Mlc1v-24 hearts, confirmed that the Mlc1v-24 transgene is expressed in cardiomyocytes (Supplementary material online, Figure S4D , arrows) but not in fibroblasts (Supplementary material online, Figure S4D , asterisks). In addition, FACS experiments for THY1 and the endothelial cell marker CD31 (cluster of differentiation 31) were performed on enzymatically isolated E18.5 heart cells ( Figure 5 and Supplementary material online, Figure S5 ). Thy1 is expressed in fibroblasts (Supplementary material online, Figure  S5A , arrows) and epicardial cells (Supplementary material online, Figure S5A , arrowheads), but not in cardiomyocytes. FACS-sorted cardiomyocytes (Thy1 2 /CD31
2 ) expressing Nkx2-5 ( Figure 5B ) and FACSsorted fibroblasts (Thy1 + /CD31
2 ) expressing Ddr2 and Thy1 ( Figure 5C ; Supplementary material online, Figure S5B , respectively) were analysed by qRT-PCR. We observed that Fgf10 is expressed in cardiomyocytes, in particular in the right ventricle, but not in cardiac fibroblasts ( Figure 5D ).
FGF receptors (FGFRs) are encoded by four genes and alternative tissue-specific mRNA splicing of Fgfr1, Fgfr2, and Fgfr3 produces FGFRs with unique ligand-binding properties. For example, while FGF3, FGF7, and FGF10 preferentially activate FGFR2b, FGF9, FGF16, and FGF20 activate FGFR2c. 11 To investigate the cell autonomy of FGF10-induced cardiomyocyte proliferation, we analysed the distribution of transcripts encoding the FGF10 receptor, Fgfr2b, by qRT-PCR. We first demonstrated that in contrast to Fgf10, Fgfr2b is expressed equivalently in the right and left ventricle at E18.5 ( Figure 5E ). Using FACS-sorted cardiomyocytes (Thy1
2 ) and fibroblasts (Thy1 + /CD31
2 ), we found that, like Fgf10, Fgfr2b transcripts accumulate in cardiomyocytes but not in fibroblasts ( Figure 5F ). In contrast, Fgfr2c transcripts are observed in both cardiomyocytes and fibroblasts (data not shown). Finally, preplating experiments after cardiac cell isolation were performed. The analysis of Fgf10 and Fgfr2b expression levels in cardiomyocyte-enriched cells (Nkx2-5 expressing; Supplementary material online, Figure S6A ) and fibroblast-enriched cells (Thy1 and Ddr2 expressing; Supplementary material online, Figure S6A ) confirmed the predominant expression of Fgf10 (Supplementary material online, Figure S6B ) and Fgfr2b (Supplementary material online, Figure S6C ) in cardiac myocytes. This evidence that both Fgf10 and Fgfr2b are expressed in cardiomyocytes strongly suggests that FGF10 controls foetal right-ventricularcardiomyocyte proliferation though a cell-type autonomous mechanism.
FGF10 promotes cell-cycle re-entry of adult cardiomyocytes in vivo
Based on our results on foetal cardiomyocytes, we then investigated whether conditional Fgf10 overexpression is able to modulate adult FGF10 controls cardiomyocyte proliferation revealed that DOX treatment led to a modest but significant increase in ventricular wall thickness ( Figure 6B ) compared with CTRL-treated mice (from 430 + 16 to 530 + 16 mm, P , 0.05 in the right ventricle and from 1008 + 30 to 1166 + 33 mm, P , 0.05 in the left ventricle). The measurement of cardiomyocyte cross-sectional area did not reveal any modification in cardiomyocyte cell size ( Figure 6C) , suggesting that Fgf10 overexpression may control adult cardiac cell numbers. We therefore examined cardiac cell proliferation using the proliferative marker Ki-67 and the mitotic marker PH3 (phosphorylated histone 3). Strikingly, DOX-treated mice display a two-fold increase of proliferation ( Figure 6D and G). Using an a-actinin antibody to identify cardiomyocytes, we showed that the observed increase in proliferation is due to proliferation of cardiomyocytes (Figure 6E and H; Supplementary material online, Figure  S7B and D) but not non-myocytes (Figure 6F and I; Supplementary material online, Figure S7C and E). We confirmed that DOX treatment of Rosa26 rtTA/rtTA mice has no impact on ventricular wall thickness and cardiomyocyte or non-myocyte proliferation (Supplementary material online, Figure S8 ). To determine a potential role of FOXO3 transcription factor in FGF10 regulation of adult cardiomyocyte proliferation, the phosphorylation status of FOXO3 protein in DOX-treated Rosa26rtTA/ rtTA;tet(O)-Fgf10 hearts was examined ( Figure 6J ). Western blot experiments revealed a significant increase in FOXO3 phosphorylation levels in DOX-treated hearts compared with CTRL-treated animals. This result suggests that FGF10 controls both foetal and adult cardiomyocyte proliferation through FOXO3-mediated downstream signalling events. We then investigated the impact of extended Fgf10 overexpression on cardiac cell proliferation. Adult Rosa26rtTA/rtTA; tet(O)-Fgf10 mice (14 weeks old) were thus induced with DOX or normal food (CTRL) for 1 week, and cardiac cell proliferation using the proliferative marker Ki-67 was analysed. Our results showed that extended Fgf10 overexpression led to a maintained increase in proliferation (two-fold, Figure 6K ) which is due to proliferation of cardiomyocytes ( Figure 6L ; Supplementary material online, Figure S9A ) but not non-myocytes ( Figure 6M ; Supplementary material online, Figure S9A ). Histological analysis of 1-week, DOX-treated Rosa26rtTA/rtTA;tet(O)-Fgf10 hearts revealed a significant increase in ventricular wall thickness compared with CTRL-treated mice (Supplementary material online, Figure S9B ) which was enhanced compared with the 2-day DOX-treated hearts (from 123 to 145% in the right ventricle and from 115 to 118% in the left ventricle). No change in cardiomyocyte cross-sectional area was observed in 1-week DOX-treated animals compared with CTRL-treated animals, confirming that FGF10 controls cardiomyocyte proliferation and not cardiomyocyte cell size (Supplementary material online, Figure S9C) .
Our results obtained in the foetal mouse heart showed that while FGF10 accumulates predominantly in the right ventricle, Fgfr2b is expressed equivalently in right and left ventricles. FGF10, to a lesser extent, can also signal through FGFR1b. 11 We thus examined the distribution of transcripts encoding Fgfr2b and Fgfr1b in the adult compared with foetal heart. Our results first revealed that, as in the foetal heart, Fgfr2b and Fgfr1b display an equivalent expression profile in adult right-and left-ventricular tissues (Supplementary material online, Figure S10 ). Interestingly, while Fgfr2b was the predominant isoform expressed in the foetal heart, expression was significantly reduced in adult heart (Supplementary material online, Figure S10A ). In contrast, the low but detectable level of Fgfr1b expression in the foetal heart was increased in the adult heart (Supplementary material online, Figure  S10B ). These results suggest that in contrast to the foetal heart, FGF10 may regulate adult cardiomyocyte proliferation predominantly through Fgfr1b.
Finally, the analysis of Fgf10 expression in the heart from foetal to adult stages using qRT-PCR assays demonstrated that while Fgf10 expression decreased during the time window where cardiomyocyte exit from the cell cycle (E18.5-postnatal day (P) 10), its expression increased at P16 to reach maximal levels at P56 (8 weeks) before decreasing at P100 (14 weeks), coinciding with the recently described brief but intense proliferative burst that occurs during the preadolescent period 30 (Supplementary material online, Figure S11 ). These results are consistent with a physiologically relevant role of FGF10 in controlling cardiomyocyte proliferation both during development and in the postnatal heart. Furthermore, maintenance of expression in the adult heart suggests a role for FGF10 in the regulation of adult heart homeostasis.
Taken together, these results showed that FGF10 is a potent regulator of adult cardiomyocyte proliferation. Indeed, a two-fold increase in Fgf10 expression is sufficient to rapidly and specifically enhance both adult right-and adult left-ventricular cardiomyocyte proliferation.
Discussion
Tight spatiotemporal control of foetal cardiomyocyte proliferation is required for normal heart morphogenesis. In this study, we identify FGF10 as a regulator of right-ventricular cardiomyocyte proliferation in the foetal heart, suggesting that regional specific programs of myocyte proliferation contribute to ventricular morphogenesis. Our results suggest that FGF10 signalling promotes foetal cardiomyocyte proliferation through a cell-type autonomous mechanism, by regulating FOXO3 phosphorylation and subsequently p27 kip1 expression levels.
Given that cardiomyocyte proliferation capacities are almost absent in the adult heart, understanding the molecular mechanisms controlling foetal proliferation is a crucial step towards cardiac regeneration strategies after injury. Here we show that FGF10, through similar intracellular signalling events to that described in the foetal heart, specifically promotes adult cardiomyocyte proliferation in vivo, suggesting a potential clinical relevance for FGF10 in cardiovascular diseases. Our data suggest that regional specific regulation of cardiomyocyte proliferation through FGF10 signalling may contribute to ventricular morphogenesis in the foetal heart. Mice lacking the major FGF10 receptor FGFR2b display thin right-and left-ventricular walls. 19 In contrast to
Fgf10 mutants which present only right-ventricular hypoplasia, the position of the cardiac apex is normal in Fgfr2b mutants, 19 raising the possibility that the regional proliferative defect observed in Fgf10 2/2 hearts may contribute to ventricular dismorphogenesis. Fgf10 was one of the first genes shown to be expressed in the second heart field. 15 In contrast to other genes expressed in this progenitor cell population, including Isl1, 31 Fgf10 is expressed in right-ventricular cardiomyocytes at E9.5 15 and, as we show here, in the foetal heart, suggesting a later role for FGF10 signalling in driving proliferation in the right ventricle. Differential myocyte proliferation has been suggested to play an important role in heart morphogenesis. Indeed, quantitative analysis of the 3D patterns of proliferation in the developing myocardium demonstrated that proliferation rates are highly regionalized. 32 In addition, using retrospective clonal analysis, regionally different patterns of oriented clonal cell growth that initiate in the early cardiac tube and persist at foetal stages have been suggested to contribute to cardiac morphogenesis. 33 Our observations provide further evidence that regional proliferative programs play an important role in cardiac-chamber-specific morphogenesis.
Our results support a model by which FGF10 signals through a celltype autonomous mechanism involving the FGFR2b receptor. Indeed, we show that Fgf10 expression is restricted to right-ventricular cardiomyocytes and that loss of Fgf10 impacts selectively on the same cell population. A non-exclusive alternative model by which FGF10 stimulates, through the activation of epicardial FGFR1 and FGFR2, migration of epicardial-derived fibroblasts that subsequently exert a pro-proliferative effect on foetal cardiomyocytes has been proposed, using WT1-Cre driven conditional inactivation of Fgfr1 and Fgfr2. 20 Our data suggest that the cardiomyocyte proliferation defects observed in Fgf10 mutant foetal hearts are likely to be independent of signal reception in epicardially derived cells. Furthermore, a recent study has shown that the mobilization and differentiation of epicardial cells are not affected after Tbx18-Cre-mediated epicardial deletion of Fgfr1 and Fgfr2, demonstrating that FGF signalling mediated by these receptors in Tbx18 positive epicardium or epicardially derived cells is not required for foetal heart development. 34 This discrepancy may potentially be explained by WT1-Cre expression in non-epicardial cell types. 35 In addition to FGFR2b, FGF10 also signals through FGFR1b; 11 however, given that conditional deletion of Fgfr1 in cardiomyocyte using the Mlc2v-Cre mouse line has no impact on heart morphogenesis 14 and that Mlc2v-Cre; Fgfr1/2 and Fgfr2b mutant mice display severe ventricular hypoplasia and thin ventricular walls 14, 19 41 Overall, the rate of cardiomyocyte proliferation gradually declines during embryogenesis. In the days after birth, cardiomyocyte proliferation ceases, myocytes become binucleated and heart growth switches from hyperplastic in foetal life to hypertrophic in postnatal life. 3 Failure of the adult mammalian myocardium to reactivate proliferation after tissue loss caused by myocardial infarction is a major barrier to the restoration of function to the damaged heart. Our results demonstrate that in addition to the regulation of foetal cardiomyocyte proliferation, FGF10 promotes adult cardiomyocyte cell-cycle re-entry. Moreover, FGF10-triggered cell-cycle re-entry is specific to cardiomyocytes and is not observed in non-myocyte cells including cardiac fibroblasts. Diverse FGF signals have been shown to be involved in the control of both foetal and adult cardiomyocyte proliferation. In vitro and in vivo experiments indicate that FGF1 treatment, in combination with p38 MAP kinase inhibition, leads to partial cardiomyocyte dedifferentiation and promotes cell-cycle progression. FGF1/p38 inhibitor injection after acute myocardial injury was described to enhance proliferation of both cardiomyocyte and endothelial cells which preserves wall thickness, reduces scaring, and improves cardiac function. Nevertheless, concomitant treatment with p38 inhibitor is required to reach maximal cardioprotective effects. 42 In vitro experiments initially described a role for FGF2 in promoting cardiomyocyte proliferation. 43 Given its properties in wound healing and angiogenesis, FGF2 was thought to be a good candidate for cardiac repair after injury. 44 Indeed analysis of Fgf2 knockout and transgenic mice revealed that FGF2, through the activation of fibroblast proliferation, endothelial cell proliferation, and cardiomyocyte hypertrophy, promotes early beneficial compensatory mechanisms after heart injury and preserves cardiac function after myocardial infarction. 45 The absence in specificity of FGF2 action, including the activation of fibroblast proliferation, might nevertheless be deleterious in a longterm treatment strategy. 46 Other FGF ligands including FGF9, FGF16, and FGF21 have been described to have a protective role upon myocardial injury. In contrast to their foetal role in cardiomyocyte proliferation, these cardioprotective effects are rather attributed to the inhibition of cardiac hypertrophy and fibrosis 47, 48 and to the enhancement of endothelial cell proliferation and microvessel formation. 49 Here we show that FGF10 is required for heart morphogenesis by promoting regional foetal cardiomyocyte proliferation and can induce rapid cellcycle re-entry specifically in adult cardiomyocytes. This suggests that FGF10 might improve the limited innate regenerative capacities of the myocardium after injury and thus potentially be of clinical relevance for heart repair. Future experiments will investigate whether FGF10-triggered cell-cycle re-entry can promote cardiac repair after myocardial infarction. Preliminary analysis of Mlc1v-24 transgene expression following myocardial infarction provides a relevant first step in this direction.
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